Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

SQI Diagnostics Inc V.SQD.H

Healthcare Medical Devices
SQI Diagnostics Inc. is a Canada-based company that is focused on lung health. The Company is engaged in the development and manufacturing of respiratory health and precision medicine tests that run on its fully automated systems. Its clinical solutions include Rapid Acute Lung Injury Diagnostic (RALI-Dx), lung transplant diagnostics, COVID-19 testing and surveillance testing solutions. Its RALI-Dx IL-6 Severity Triage Test and the RALI-fast IL-6 Severity Triage point of care (POC) Test each help clinicians identify which patients with SARS-CoV-2 are predicted to have a severe inflammatory response and should or should not be admitted to the hospital. Its RALI-Dx delivers results from the lab in less than an hour while RALI-fast delivers results at the patient point-of-care in about 15 minutes. The Company’s TORdx LUNG Test measures inflammation at the molecular level to assess the health of the donor lung. The Company is also focused on its organ transplant pipeline of products.


TSXV:SQD.H - Post by User

SQI Diagnostics Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(494)
•••
Post by FactFinder1994on Apr 05, 2023 3:19pm
236 Views
Post# 35381684

UHN - LUNG BIOENGINEERING - SQI DIAGNOSTICS

UHN - LUNG BIOENGINEERING - SQI DIAGNOSTICS Massive incentives for all

United Therapeutics (Lung Bioengineering) 
EVLP (UHN Toronto Protocol) is in the most near term pipeline category, with confirmatory FDA trial nearing completion.

Navigate the UT site link here below & Learn More - you will confirm that in 2019 the PREVALENCE of END-STAGE LUNG DISEASE at equal to 600,000 patients annually in the USA.  

Thousands of lives have now been saved with refurbished lungs as a result of EVLP.  

SQI's TORdx is an important advancement that fulfills Shaf Keshavjee's Vision for PRECISION therapeutics/medicine/treatment.  

This should no longer be off the radar, but rather front and center.  The SQI story is important - please share it.  Thousands of lives and Billions of dollars here...          

Complete Pipeline
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities